NCT05370976
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Phase: Phase 2
Role: Collaborator
Start: Sep 13, 2022
Completion: Aug 24, 2023